BTG
This article was originally published in The Gray Sheet
Executive Summary
British firm acquires U.S. and European rights from Oxford University scientists to noninvasive procedure for detecting fetal DNA in maternal serum or plasma samples. Technology likely will be applicable to prenatal screening for various inherited disorders, including Down's syndrome. Concept is based on a determination that an unborn baby's DNA can "find its way" into the mother's serum, and then DNA analysis can be performed to look for genetic disorders. BTG is searching for commercial partners
You may also be interested in...
Alvotech Highlights Lack Of Simponi Rivals As It Delivers Golimumab Results
Alvotech has just become the first company to announce positive topline results from a confirmatory clinical study for a proposed golimumab rival to Simponi and Simponi Aria – and moreover, the firm sees limited competition from other biosimilars on the horizon.
Xbrane Assembles The Troops As FDA Says No To Lucentis Biosimilar
Xbrane Biopharma was riding the crest of a wave with the EU launch of its biosimilar to Lucentis, following years of toil and investment. However, plans to roll out the product in the US will have to be pushed back – likely – into the middle of 2025, following a US FDA complete response letter.
UK MHRA Updates Assistive Tech And Borderline Regulations
Device classification themes were uppermost in April for the UK regulator, which issued key guidance in two areas prone to complexities. It also contributed to the MedTech Directorate’s one-year progress report.